ACOG committee opinion. No. 336: Tamoxifen and uterine cancer.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 16738185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tamoxifen may be associated with endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma, and uterine sarcoma. Any symptoms of endometrial hyperplasia or cancer reported by a postmenopausal woman taking tamoxifen should be evaluated. Premenopausal women treated with tamoxifen have no known increased risk of uterine cancer and as such require no additional monitoring beyond routine gynecologic care. If a typical endometrial hyperplasia develops, appropriate gynecologic management should be instituted, and the use of tamoxifen should be reassessed.
Medical subject headings
- Endometrial Neoplasms
- Selective Estrogen Receptor Modulators
- Tamoxifen
- Uterine Neoplasms